# Rumors Surface of Management Buyout at Novartis Amid Leadership Split and Cash Flow Crisis

**Source:** Financial Times  
**Author:** Michael Thompson  
**Date:** September 22, 2025

## Summary
Industry sources report growing speculation about a potential management-led buyout of pharmaceutical giant Novartis, driven by internal leadership divisions over strategic direction and mounting cash flow pressures from orbital manufacturing investments.

## News Report

Rumors of a potential management-led leveraged buyout of Swiss pharmaceutical giant Novartis have intensified following reports of deep divisions within the company's senior leadership team and mounting financial pressures from ambitious space-based manufacturing investments.

Sources close to the company suggest a faction of senior executives, including Chief Information Officer Dr. Andreas Weber and several divisional heads, are advocating for a dramatic strategic refocus on seasonal disease treatments, which they argue represents Novartis's core competitive advantage and most profitable market segment.

"There's a fundamental disagreement about the company's future direction," said one industry insider who requested anonymity. "The CIO and his allies believe Novartis has overextended itself with costly orbital manufacturing projects while neglecting its bread-and-butter seasonal disease portfolio that generates the most reliable revenue streams."

The internal tensions have reportedly escalated following the company's €2.8 billion investment in the European Space Agency's orbital water refining facility, which some executives view as a risky distraction from traditional pharmaceutical operations. While the ultra-pure water production has shown promising results, the massive capital requirements have strained the company's cash position.

Financial analysts have noted concerning trends in Novartis's quarterly reports, with free cash flow declining 40% year-over-year as the company funds multiple orbital manufacturing initiatives. The cash flow crisis has reportedly prompted discussions about divesting non-core assets and potentially restructuring the entire organization.

The rumored management buyout would allegedly involve the faction seeking to refocus on seasonal diseases, with preliminary discussions suggesting they would seek to take the company private to implement their strategic vision without public market pressures. Industry sources estimate such a transaction could value Novartis at approximately €180 billion.

Neither Novartis nor the executives allegedly involved in buyout discussions have responded to requests for comment. The company's stock has declined 15% over the past month amid the swirling speculation and concerns about the sustainability of its current strategic direction.

The potential buyout highlights broader questions about pharmaceutical companies' expansion into space-based manufacturing and whether such investments represent genuine innovation or costly diversions from core healthcare missions.
